linjc16/ctgov huggingface dataset:
Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients

Study Overview
=================
Brief Summary
-----------------
Angiographies of the supra-aortic vessels by magnetic imaging have become common recently. So it was the purpose of this study to evaluate the imaging potential of different contrast agents. Three contrast agents for magnetic resonance imaging are compared in angiographies of the supra-aortic arteries in a intraindividual study of 10 patients. All applications of these contrast agents are performed with a flow of 2 ml/s. One contrast medium is applicated a second time with a reduced flow of 1 ml/s. The angiographies of the supra-aortic vessels are evaluated by two experienced readers in a consensus reading. The signal/noise- and contrast/noise-ratio of anatomic vessel segments of the carotic and vertebral arteries are measured and compared to each other.

Official Title
-----------------
Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging

Conditions
-----------------
Headache, Epilepsy, Dizziness

Intervention / Treatment
-----------------
* Drug: Contrast agent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Headache Epilepsia Dizziness Exclusion Criteria: Pregnancy Metal implants (e.g. pacemaker) Contraindication for contrast agent Multiple allergies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Contrast agent|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intensity of vessels, muscle, air |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| signal/noise ratio |  |  | 
| contrast/nose ratio |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
magnetic imaging, angiography, contrast agent, signal/noise ratio, contrast/noise ratio, vessel
Breast Study Investigating a New Light Technique to Monitor Changes in Breast Tissue Density

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the ability of a technique called Transillumination Breast Spectroscopy (TIBS) to monitor an individual's breast density changes over time.

Detailed Description
-----------------
Breast density is an established physical risk factor for breast cancer, applicable to the entire female population in a pre-breast-screening program and, unlike other risk factors, was shown to be affected by an intervention treatment. High breast tissue density is associated with increased risk of breast cancer. Transillumination Breast Spectroscopy (TIBS) uses a white light to provide spectral information on breast tissue density and composition (e.g. water, lipid, hemoglobin and other biomolecules). The overall goal of the TIBS program is to develop a technique that can identify individuals at high risk for breast cancer who would benefit most from improved screening methods and a risk reducing intervention (e.g. diet and lifestyle changes) and can monitor the efficacy of the risk reducing intervention itself in an individual. In a previous study, we demonstrated a high correlation between breast density assessed by TIBS and density identified by x-ray mammography. The current study is testing TIBS ability to monitor changes in an individual's breast density over time

Official Title
-----------------
Optical Quantification of Breast Density Changes Due to Hormone Treatment, Pregnancy and Breast-feeding.

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be in good health and able to provide consent Be between 25 and 45 years of age Be pre-menopausal Are willing to come in to Princess Margaret Hospital (Toronto, Ontario, Canada) for up to 12 visits at intervals of about three months Exclusion Criteria: Have had a full term pregnancy Have had breast biopsy Have had breast augmentation or reduction

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Transillumination Spectroscopy, Optical Transillumination Spectroscopy, Breast Cancer Risk
Non-comparative Study to Assess the Visual Performances and Safety of a Progressive Multifocal Intraocular Lens

Study Overview
=================
Brief Summary
-----------------
This is an interventional, non-controlled, multicenter international trial with a prospective design on one cohort of patients.

Detailed Description
-----------------
To evaluate if the positive results (to assure a good visual acuity at all distances and a good quality of life in terms of glasses independence and absence of undesired events), obtained experimentally using the IOL MINI WELL READY, can be confirmed in the practical surgical routine with a population belonging to different EU countries

Official Title
-----------------
An Open Label, Non-comparative Study to Assess the Visual Performances and Safety of a Progressive Multifocal Intraocular Lens With Extended Depth of Focus

Conditions
-----------------
Cataract, Presbyopia

Intervention / Treatment
-----------------
* Device: IOL MINI WELL READY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any gender and age above 18 years. Refractive lens exchange (RLE) or cataract surgery. Healthy corneas, not treated surgically. Patients willing to have surgery in both eyes in a short period of time (within 2 weeks). Patients request to receive the IOL MINI WELL READY implant Exclusion Criteria: Previous corneal surgery (i.e. pterygium, refractive surgery). Eye diseases determining a probable postoperative visual acuity < 20/40. Pseudoexfoliation. Abnormal pupil size and position. Use of contact lens 30 days before the preoperative visit. Corneal warpage. Predicted postoperative corneal astigmatism higher than 1 D.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single arm receiving Mini WELL Ready IOL<br>IOL implantation for cataract | Device: IOL MINI WELL READY<br>* IOL MINI WELL READY<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| UDVA (Uncorrected Distance Visual Acuity) | Visual acuity mesurement | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Device Effects (ADE); Serious Adverse Device Effects (SADE); Unexpected Serious Adverse Device Effects (USADE); Adverse Events (AE); Serious Adverse Events (SAE). | Safety assessment | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Refractive lens exchange (RLE) or cataract surgery
Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to explore the concept of GnRH-agonist triggering in combination with elective cryopreservation of all 2PN oocytes at larger scale in a pragmatic clinical setting. The question asked is: Does GnRH-agonist triggering and cryopreservation work, in terms of efficacy and safety, when applied to a larger cohort of patients, and by a number of different centres with different clinical routines.

Official Title
-----------------
OHSS Prevention by GnRH-agonist Triggering of Final Oocyte Maturation and Cryoperservation of All Two-pronucleate Oocytes in Women Undergoing Stimulation for IVF With Gonadotrophins and GnRH-analogues: a Prospective, Observational, Multicentric, Clinical Cohort Study

Conditions
-----------------
Ovarian Hyperstimulation Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication for IVF with ICSI Age < 40 years < 4 failed previous IVF attempts with embryo transfer ovarian stimulation with GnRH-antagonist and gonadotrophins >20 follicles >11 mm in mean diameter or E2 >4500 pg/ml on the day , on which it was planned to administer hCG willing to participate and able to consent patient has not previously received GnRH-agonist as a trigger of final oocyte maturation Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| OHSS risk<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cumulative ongoing pregnancy rate (10-12 GWs) per patient within 12 months |  | 12 months after recruitment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ongoing pregnancy rate/frozen-thawed ET |  | 12 months after recruitment | 
| Ongoing pregnancy rate/first frozen-thawed ET |  | 12 months after recruitment | 
| time to pregnancy in weeks |  | 12 months after recruitment | 
| incidence of OHSS III° |  | 12 months after recruitment | 
| number of cumulus-oocyte-complexes |  | 12 months after recruitment | 
| fertilization rate (number COCs/number of 2 PN oocytes |  | 12 months after recruitment | 
| survival rate (number of vital embryos/number of frozen 2 PN oocytes |  | 12 months after recruitment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GnRH agonist, frozen-thawed embryo replacement, GnRH antagonist, ovarian hyperstimulation
Improving HPV Vaccination Rates Among Rural and Native American Adolescents

Study Overview
=================
Brief Summary
-----------------
This study will develop and implement a multi-level intervention aimed at improving human papillomavirus (HPV) vaccination rates at an Indian rural health clinic.

Detailed Description
-----------------
The focus of this study is to develop, implement, and evaluate a human papillomavirus (HPV) vaccination program aimed at accelerating vaccine uptake among rural and Native American adolescents ages 11-17. HPV vaccination coverage with at least one dose remains disproportionately lower among rural adolescent compared to adolescents residing in urban areas and the rate of series completion is lower among Native American adolescent girls compared to non-Hispanic White adolescent girls.

Official Title
-----------------
Accelerating Uptake of the HPV Vaccine Among Rural and Native American Adolescents

Conditions
-----------------
HPV Vaccinations

Intervention / Treatment
-----------------
* Behavioral: HPV vaccination training and education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinic patients between the ages of 11-17 who are eligible for the HPV vaccine Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 11 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HPV Vaccination Training and Education<br>Participants will be educated on the importance of HPV vaccination. | Behavioral: HPV vaccination training and education<br>* 1) Training of providers and clinic staff on the importance of providing a strong HPV vaccination program and 2) HPV vaccination education for parents and the community.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinic HPV Vaccination Rates | HPV vaccine uptake rates (initiation and completion of the 2-dose series) among clinic patients aged 11-17 as measured by the HPV ICD code from baseline to post. | One year |
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

Study Overview
=================
Brief Summary
-----------------
This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

Official Title
-----------------
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: Pyrotinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients should be histologically diagnosed with metastatic colorectal cancer or postoperative recurrence; Patients with ALK mutation(including mutation, fusion, rearrangements ); Patients have measurable lesions; Patients are not available for targeted therapy or patients refuse to receive targeted therapy afer second-line treatment; Over 3 weeks after radiotherapy and the radiotherapy focus was not be measured; Age should be 18-25 years; Performance status should be 0-2; Life expectancy should be more than 12 weeks; Exclusion Criteria: Patients underwented major surgery or severe trauma within 4 weeks; Patients allergiced to experimental drugs; Patient ready to give birth or who is pregnant; Patients with brain metastases; Patients with chemotherapy contraindication; Patients could not tolerate chemotherapy; Patients have secondary primary tumor.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HER2-positive Metastatic Colorectal Cancar<br> | Drug: Pyrotinib<br>* Pyrotinib in Combination With Trastuzumab<br>* Other names: Trastuzumab;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Rate(ORR) | Evaluation of tumor burden based on RECIST criteria. | up to 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HER2, Pyrotinib, Trastuzumab, Metastatic Colorectal Cancar
Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the level of neutralizing antibody against SARS-CoV-2 after COVID-19 vaccination in patients under hemodialysis. To this end, the level of neutralizing antibody of patients under hemodialysis is compared to that of healthy population.

Official Title
-----------------
Evaluation of Protective Antibody Production After COVID-19 Vaccination Among Patients Under Hemodialysis

Conditions
-----------------
Covid19, End-stage Renal Disease, Vaccine Reaction, Hemolysis

Intervention / Treatment
-----------------
* Diagnostic Test: Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The person who is vaccinated with ChAdOx1 (COVID-19 vaccine) The person who agrees with the protocol of the study Exclusion Criteria: Age < 18 years Pregnants Experience of COVID-19 infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)|The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change in the level of neutralizing antibody against SARS-CoV-2 |  | Day 0, 14, 28, 56, 91, 120 |
A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This single center, open-label, non-randomized, one-treatment, one-period study will evaluate the metabolic profile and the safety of a single oral radiolabeled dose of dalcetrapib in male healthy volunteers.

Official Title
-----------------
An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Drug: dalcetrapib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male subjects, 45 to 65 years of age inclusive Body mass index (BMI) between 18 and 32 kg/m2 inclusive Exclusion Criteria: Any concomitant disease or ongoing condition that in the investigator's opinion could interfere with the study or could pose an unacceptable risk to the subject Clinically significant abnormal laboratory values Infrequent bowel movements (e.g. less than one movement per 24 h on average) An intent to father children within 3 months of dosing Any external or internal radiotherapy with open (nuclear medicine) or sealed sources (brachy therapy) External irradiation (radiological examination) or internal radiation (diagnostic nuclear medicine procedure) within one year before study drug dosing; dental radiography and plain X-rays of the extremities are allowed before dosing

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single Arm<br> | Drug: dalcetrapib<br>* Single oral radiolabeled dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic Profile: Percentage of Free Thiophenol M1 in the Blood Plasma |  | up to Day 5 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Metabolic Profile With Enzyme/Transporter Genotypes |  | approximately 3 months |
Effect of Kinesio Taping in Muscle Fatigue

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to determine the effect of Kinesio taping on lactic acid in an running anaerobic test.

Official Title
-----------------
Effect of Kinesio Taping in Muscle Fatigue

Conditions
-----------------
Muscle Fatigue

Intervention / Treatment
-----------------
* Procedure: Kinesio Tape Method


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: They should practice physical activity 2-4 days a week. Exclusion Criteria: History of surgery in the lower limbs Muscle-tendon injury or trauma in the lower limbs (LL) in the last six months cardiovascular and / or respiratorydisease Any allergies related to the bandage material.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Kinesio Tape Group<br>muscle Kinesio Taping in Triceps Surae, Tibialis anterior, and Quadriceps according Kenzo Kase Method | Procedure: Kinesio Tape Method<br> <br> |
| No Intervention: Control group<br>They will do the same measurement of lactate and exercise protocol in treadmill, but always without kinesio tape intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in capillary blood acid lactate |  | Participants will be measured four times to follow the changes of lactate: Baseline (Pre Exercise), immediately post exercise, 5 minutes post exercise and 15 minutes post exercise. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bandage, Treadmill, Lactate Acid